evERA: Giredestrant Plus Everolimus Extends PFS After CDK4/6 Inhibitor Failure

The phase 3 evERA Breast Cancer trial has reported that giredestrant, an investigational oral selective oestrogen receptor degrader, combined with everolimus, extended progression-free survival compared with standard endocrine therapy plus everolimus in patients with ER-positive, HER2-negative advanced breast cancer that had progressed after a CDK4/6 inhibitor. The results were published in the New England Journal of Medicine on 1 October 2026 (Mayer EL, Tolaney SM, Martín M, et al. N Engl J Med 2026;395(13):1285-1298).

Median progression-free survival was 8.8 months with the giredestrant combination versus 5.5 months with the control regimen in the intention-to-treat population (hazard ratio 0.56; 95% CI 0.44 to 0.71; p<0.001). In the prespecified subgroup with ESR1 mutations, median progression-free survival was 10.0 months versus 5.5 months (stratified hazard ratio 0.38; 95% CI 0.27 to 0.54; p<0.001). Both co-primary endpoints were met.

The clinical gap the trial addresses

For ER-positive, HER2-negative metastatic breast cancer, first-line treatment is a CDK4/6 inhibitor plus endocrine therapy. That combination works well and for a long time in many patients, but it is not curative, and what to do next is one of the less settled questions in the field.

Resistance after a CDK4/6 inhibitor is heterogeneous. One well-characterised mechanism is the acquisition of activating mutations in ESR1, the gene encoding the oestrogen receptor. These mutations produce a receptor that is constitutively active and no longer depends on oestrogen binding, which makes aromatase inhibitors, whose entire mechanism is to lower circulating oestrogen, largely ineffective. ESR1 mutations are rarely present at diagnosis and accumulate under the selective pressure of endocrine therapy. A second common route runs through the PI3K/AKT/mTOR pathway, which can sustain proliferative signalling independently of the receptor.

Both mechanisms have been targeted separately. Fulvestrant, an injectable SERD, degrades the receptor rather than depriving it of ligand, and so retains activity against mutant receptor. Oral SERDs have extended that approach: elacestrant was approved in January 2023 and imlunestrant in September 2025, both as single agents for ESR1-mutated disease after prior endocrine therapy. Camizestrant has been authorised in the European Union in combination with a CDK4/6 inhibitor for patients in whom an ESR1 mutation is detected in blood during first-line therapy, before radiographic progression, on the basis of the SERENA-6 trial. Separately, everolimus, an mTOR inhibitor, has been combined with exemestane since the BOLERO-2 era to interrupt the downstream pathway.

What evERA tested is whether attacking both at once does better than attacking one. The control arm was not a placebo: every patient received everolimus. The question was therefore narrow and clinically useful — given that you are adding mTOR inhibition, does a next-generation oral SERD serve as a better endocrine backbone than the agents currently used in that position?

How giredestrant works

Giredestrant is an oral, investigational next-generation SERD and full oestrogen receptor antagonist. It blocks oestrogen from binding the receptor and promotes the receptor's degradation, so the protein itself is depleted rather than merely blocked. Because the mechanism does not depend on lowering circulating oestrogen, it remains relevant when the receptor has become ligand-independent through mutation — which is the mechanistic rationale for the larger effect seen in the ESR1-mutated subgroup.

Everolimus addresses the other axis. By inhibiting mTOR, it blunts signalling through the PI3K/AKT/mTOR pathway, one of the routes by which cells escape endocrine control. Combining a SERD with an mTOR inhibitor is an attempt to close both escape routes in the same regimen, in patients who have already demonstrated that endocrine therapy alone is no longer holding.

Trial design

evERA Breast Cancer (NCT05306340) was a global, randomised, open-label, multicentre phase 3 trial.

• Population: ER-positive, HER2-negative locally advanced or metastatic breast cancer with progression or recurrence after a CDK4/6 inhibitor plus endocrine therapy, given in either the adjuvant or the advanced setting.
• Randomisation: 373 patients, 1:1.
• Experimental arm: giredestrant plus everolimus.
• Control arm: investigator's choice of standard endocrine therapy — exemestane, fulvestrant or tamoxifen — plus everolimus.
• Co-primary endpoints: investigator-assessed progression-free survival in the intention-to-treat population and in the ESR1-mutated population.
• Key secondary endpoints: overall survival, objective response rate, duration of response, clinical benefit rate and safety.

ESR1 mutations were present in 55.5% of the overall population, giving 207 patients in that cohort. Median follow-up was 18.6 months. The trial was open-label, which is a real limitation for an investigator-assessed progression endpoint; the published report states that blinded independent central review was comparable to the investigator assessment, which is the appropriate check on that bias.

Results in detail

The separation in progression-free survival was driven substantially, but not entirely, by the ESR1-mutated group. The hazard ratio of 0.38 in that cohort corresponds to a 62% reduction in the risk of progression or death; the figure of 0.56 in the full population corresponds to 44%. Some coverage of the trial has quoted a 63% reduction for the ESR1-mutated group, which reflects rounding of the same hazard ratio rather than a different analysis. Notably, the control arm's median progression-free survival was 5.5 months in both populations, so the difference between cohorts came from the experimental arm.

Benefit was reported as consistent across most key subgroups, including patients with PIK3CA, AKT1 or PTEN alterations, and regardless of the duration or type of prior CDK4/6 inhibitor or which endocrine agent was used in the control arm.

Overall survival data were immature at this analysis and did not reach statistical significance. In the intention-to-treat population, at 67% maturity, estimated 18-month overall survival was 75.1% versus 62.0% (hazard ratio 0.69; 95% CI 0.47 to 1.00). In the ESR1-mutated population, at 59% maturity, it was 71.5% versus 50.9% (hazard ratio 0.62; 95% CI 0.38 to 1.02). Both confidence intervals include or touch 1.00, so these are trends and not conclusions. Follow-up continues. Objective response rate, duration of response and clinical benefit rate were secondary endpoints but have not been reported in the coverage available at the time of writing; they appear in the full publication.

Safety

Adverse events of any grade occurred in 98.9% of patients on giredestrant plus everolimus and 96.8% on standard endocrine therapy plus everolimus — essentially universal in both arms, which is expected with everolimus in the backbone. The most common events were similar between arms: stomatitis in 47.3% versus 48.9%, diarrhoea in 26.9% versus 22.6%, and anaemia in 23.6% versus 21.0%.

The investigators reported no unexpected safety findings and described the profile as consistent with the known toxicities of the individual agents. Two class-specific concerns for oral SERDs were addressed directly: photopsia, the visual disturbance seen with some agents in this class, was not observed, and bradycardia rates were low. Grade 3 and higher event rates, dose reductions and treatment discontinuation rates are in the published report but were not included in the summaries available for this article, and they matter for judging tolerability in practice.

Where this sits in the treatment sequence

The practical significance depends on how the regulatory decisions land. The US FDA has accepted a new drug application for giredestrant plus everolimus in ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer, with a target action date of 18 December 2026. A separate application for adjuvant giredestrant in stage I to III disease, based on the lidERA trial, is under priority review with a target date of 30 November 2026.

If the advanced-disease application is approved as filed, the indication would be confined to the ESR1-mutated population, where the effect is largest, even though the trial met its endpoint in the full population as well. That would place the combination alongside existing oral SERD options in the same biomarker-defined group, with the distinction that it is a combination with an mTOR inhibitor rather than single-agent endocrine therapy — a more active regimen, but also one with everolimus toxicity in every patient.

evERA was the first of five company-sponsored phase 3 trials of giredestrant to report positively, followed by lidERA in the adjuvant setting. Three others — persevERA, pionERA and heredERA — are testing the drug in endocrine-sensitive advanced disease, after adjuvant endocrine resistance, and in HER2-positive disease respectively.

What to watch

• Mature overall survival. The progression-free survival result is clear, but the survival hazard ratios are immature and their intervals cross or touch unity. Longer follow-up will determine whether the delay in progression translates into longer life.
• The two PDUFA dates. Decisions are expected on 30 November 2026 for adjuvant giredestrant and 18 December 2026 for the advanced-disease combination.
• Detailed tolerability. Grade 3 and higher rates and discontinuation figures will determine whether a doublet is a realistic option in heavily pretreated patients compared with a single-agent oral SERD.
• Sequencing evidence. With several oral SERDs now available or approaching approval, and camizestrant moving the class into the pre-progression setting, the open question is which agent to use when — a question no single trial in this programme is designed to answer.
• The non-mutated population. The trial met its endpoint in the full population, but a biomarker-restricted indication would leave the benefit shown in ESR1-wild-type patients without a route into practice.

This article is for information only and is not medical advice. Treatment decisions should be made with a qualified clinician.

Sources: Roche; CancerNetwork; The ASCO Post; Targeted Oncology; ClinicalTrials.gov NCT05306340